Catalyst Dossier · compiled by Celia 🧫

PFIZER (PFE)

Pharmaceutical Preparations · market cap $143.7B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Pfizer Inc. is a large-cap multinational pharmaceutical company with a $143B market cap, 75,000 employees, and a broad, late-stage pipeline spanning oncology, immunology, vaccines, metabolic disease, and CNS indications. The company generated $62.6B in revenue and $7.8B in net income in 2025, though both figures reflect a meaningful step-down from the 2022 COVID-era peak of $100.3B. Despite a robust pipeline with multiple Phase 3 assets and several high-importance catalysts in the coming months, the balance sheet carries $62.8B in net debt, a significant overhang.

The catalyst path

2026-08-04Earningsimp 5/10
2026-08-23 (est.)Phase 2 · PF-07220060 + PF-07104091 combination dose escalationimp 7/10
2026-08-30 (est.)Phase 3 · Elotuzumabimp 9/10
2026-09-15 (est.)Phase 2 · MET233 and MET097imp 7/10
2026-09-21 (est.)Phase 2 · PF-07275315imp 7/10
2026-09-23 (est.)Phase 2 · PF-07220060imp 7/10
2026-10-08 (est.)Phase 3 · Rimegepantimp 9/10
2026-10-19 (est.)Phase 2 · PF-07264660imp 7/10

Pipeline

Asset	Phase	Indication
DVS-233 SR (desvenlafaxine sustained release )	Phase 3	Major Depressive Disorder
Insulin Lispro	Phase 3	Diabetes Mellitus
Cyclosporine A	Phase 3	Renal Transplantation
Prednisone	Phase 2	Prostatic Neoplasms
PF-06826647	Phase 2	Psoriasis
13 valent pneumococcal conjugate vaccine with Polysorbate 80	Phase 3	Vaccines, Pneumococcal
Meropenem	Phase 3	Complicated Intra-abdominal Infections
MET097	Phase 3	Obesity
RSVpreF (Group 1)	Phase 3	RSV
Imipenem-cilastatin	Phase 3	Skin Infection
Diclofenac	Phase 3	Spondylitis, Ankylosing
PF-07850327, ARV-471, vepdegestrant	Phase 2	Locally Advanced or Metastatic ER+ HER2- Breast Cancer
CP-690-550	Phase 2	Arthritis, Rheumatoid
SU-011,248	Phase 2	Kidney Neoplasms
Pediacel	Phase 3	Vaccines, Pneumococcal
Pemetrexed/Cisplatin	Phase 3	NSCLC (Non-small Cell Lung Cancer)
Multivalent Pneumococcal Vaccine - Formulation 1	Phase 2	Pneumococcal Disease
0.04 mg/kg CpG 7909	Phase 2	Carcinoma, Breast
PF-04217329 - Lowest Dose	Phase 2	Primary Open-Angle Glaucoma
Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral	Phase 2	Osteoarthritis of the Knee

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.